OQRO

Feed News

Explore

Insider trades Fund moves Congressional trades Federal contracts Screener

Yours

Watchlist Alerts Saved Ask Claude or ChatGPT

Create a free account Sign in

OQRO

Search/

Loading…

Officer received an award of 31K COLL shares | OQRO

Home
Insider trades
Collegium Pharmaceutical, Inc.
Officer received an award of 31K COLL shares

Insider trades

Insider trade

Officer received an award of 31K COLL shares

Traded Feb 10, 2026 · Filed Feb 12, 2026

COLCollegium Pharmaceutical, Inc.COLL

31K
Shares

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 10, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 12, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0001746251-26-000002
Filed / recorded

Ask Claude or ChatGPT about these filings. Connect OQRO in a minute, then ask things like “which insiders bought this week?”

Feb 12, 2026, 9:30 PM UTC

Added to OQRO

Oct 6, 2026, 10:35 PM UTC

Parser

form4-xml-v2

Data quality

Verified: identifiers matched exactly

Issuer

COLLEGIUM PHARMACEUTICAL, INC

Issuer CIK

1267565

Ticker

COLL

Reporting person

Scott Dreyer

Relationship

Officer

Officer title

EVP & Chief Commercial Officer

Security

Common Stock

Table

Non-derivative (Table I)

Transaction date

Feb 10, 2026

Transaction code

Shares / units

30,702

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

153,338

Ownership form

Direct

Amendment

Footnotes from the filing

Effective February 10, 2026, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to an aggregate of 30,702 performance share units ("PSUs") granted in the Issuer's three prior fiscal years.

Around the same time

David Dieter (EVP & General Counsel) sold ~$228K of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 7mo ago

Scott Dreyer (EVP & Chief Commercial Officer) sold ~$1.87M of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 7mo ago

Scott Dreyer (EVP & Chief Commercial Officer) sold ~$146K of Collegium Pharmaceutical, Inc.

Scheduled in advanceFiled 7mo ago